Business Wire

Agreement will leverage ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemiaLONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and...

HANOI, Vietnam--(BUSINESS WIRE)--When it comes to selecting a vehicle, there's no denying the allure of sleek lines, captivating contours, and eye-catching aesthetics. Design matters-a lot. In fact, studies have shown that nearly 40% of car buyers consider design as...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Bernd Schmidt,...

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Meilleur Technologies, Inc. today announced a research collaboration agreement with the Young Blood Institute (YBI) on the use of Meilleur’s NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status of amyloid...

HOUSTON--(BUSINESS WIRE)--SilverBow Resources, Inc. (NYSE: SBOW) (“SilverBow” or the “Company”) today announced the upsize and pricing of a previously announced underwritten public offering of its common stock (the “Offering”) by an affiliate of Strategic Value Partners, LLC (the “Selling...

LONDON--(BUSINESS WIRE)--His Excellency Mr. Félix Antoine Tshisekedi Tshilombo, President of the Democratic Republic of Congo, has met in Kinshasa with members of the law firm Amsterdam & Partners LLP, which has been retained by the Government of the DRC...

Collaboration leverages the proven development and commercial capability of Ferring with PharmaBiome’s compelling technology to research, develop and manufacture novel donor-independent microbiome-based therapies Deal provides access for Ferring to the next generation of microbiome-based therapies, building on Ferring's long term...

SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in patients with R/R AML with 5 complete...

In TRANSCEND FL, 95.7% of patients with high-risk relapsed or refractory follicular lymphoma (FL) treated with Breyanzi in the second-line setting achieved a complete response, with median duration of response and median progression-free survival not reached at a median...

CHICAGO--(BUSINESS WIRE)--#ChicagoBoothExecEd--The University of Chicago Booth School of Business introduces The Chicago Booth Approach to Finance Workshop (CBAFW), a transformative program designed for managers without accounting and financial backgrounds who wish to develop a solid understanding of measuring and...